On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ: RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Recursion Pharmaceuticals owns the largest supercomputer in the pharmaceutical industry. However, Eli Lilly is starting to build one that could be even more powerful once it's completed. With its ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals stock jumped 16% on October 8, 2025, reaching around $6.08 after falling 5.4% the previous day on broader market weakness. The company reported Q2 2025 revenue of $19.2 ...

Finding the right keywords is crucial for getting past an ATS and putting your resume into the hands of the hiring manager. The applicant tracking system, often referred to as ATS, is the employer’s ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

in Oracle a recursive CTE unfortunately cannot be marked with the recursive keyword (despite the ANSI standard) and in Postgres it must be marked with "recursive". In Oracle a CTE is inherently ...